Hypoxanthine phosphoribosyltransferase activity in intact fibroblasts from patients with X linked hyperuricemia

M. J C Holland, A. M. DiLorenzo, J. Dancis, M. E. Balis, T. F. Yü, R. P. Cox

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Discordance between clinical phenotype and the level of a mutant enzyme activity may reflect differences between enzyme function in vivo and that measured by the customary enzyme assays on cell extracts. In the present study, the conversion of hypoxanthine to phosphorylated products was measured in intact skin fibroblasts and in cell extracts from seven patients with mutant hypoxanthine guanine phosphoribosyltransferase (HPRT) and six control subjects. The patient's phenotypes ranged from asymptomatic hyperuricemia to the Lesch Nyhan syndrome. Although there was a general correlation between the HPRT activity in cell extracts assayed by the usual methods and the function of the purine salvage pathway in patients, as reflected by urinary oxypurine excretion, there were notable exceptions. A more accurate appraisal of the functioning of the pathway at the cellular level is achieved by measuring the conversion of substrate to product in the intact cell at physiological concentrations of substrates, activators, and product and metabolite inhibitors, and in a physiological ionic environment. In one of the seven patients, the standard enzyme assay indicated normal function, whereas measurements in the intact cell exposed severe dysfunction of the salvage system. In another, the standard assay suggested a severe deficiency not evident in the intact cell or in the patient.

Original languageEnglish (US)
Pages (from-to)1600-1605
Number of pages6
JournalJournal of Clinical Investigation
Volume57
Issue number6
StatePublished - 1976

Fingerprint

Lesch-Nyhan Syndrome
Hypoxanthine Phosphoribosyltransferase
Fibroblasts
Cell Extracts
Enzyme Assays
Phenotype
Hyperuricemia
Hypoxanthine
Enzymes
Skin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hypoxanthine phosphoribosyltransferase activity in intact fibroblasts from patients with X linked hyperuricemia. / Holland, M. J C; DiLorenzo, A. M.; Dancis, J.; Balis, M. E.; Yü, T. F.; Cox, R. P.

In: Journal of Clinical Investigation, Vol. 57, No. 6, 1976, p. 1600-1605.

Research output: Contribution to journalArticle

Holland, M. J C ; DiLorenzo, A. M. ; Dancis, J. ; Balis, M. E. ; Yü, T. F. ; Cox, R. P. / Hypoxanthine phosphoribosyltransferase activity in intact fibroblasts from patients with X linked hyperuricemia. In: Journal of Clinical Investigation. 1976 ; Vol. 57, No. 6. pp. 1600-1605.
@article{78d26051774e4107a10c793b21949622,
title = "Hypoxanthine phosphoribosyltransferase activity in intact fibroblasts from patients with X linked hyperuricemia",
abstract = "Discordance between clinical phenotype and the level of a mutant enzyme activity may reflect differences between enzyme function in vivo and that measured by the customary enzyme assays on cell extracts. In the present study, the conversion of hypoxanthine to phosphorylated products was measured in intact skin fibroblasts and in cell extracts from seven patients with mutant hypoxanthine guanine phosphoribosyltransferase (HPRT) and six control subjects. The patient's phenotypes ranged from asymptomatic hyperuricemia to the Lesch Nyhan syndrome. Although there was a general correlation between the HPRT activity in cell extracts assayed by the usual methods and the function of the purine salvage pathway in patients, as reflected by urinary oxypurine excretion, there were notable exceptions. A more accurate appraisal of the functioning of the pathway at the cellular level is achieved by measuring the conversion of substrate to product in the intact cell at physiological concentrations of substrates, activators, and product and metabolite inhibitors, and in a physiological ionic environment. In one of the seven patients, the standard enzyme assay indicated normal function, whereas measurements in the intact cell exposed severe dysfunction of the salvage system. In another, the standard assay suggested a severe deficiency not evident in the intact cell or in the patient.",
author = "Holland, {M. J C} and DiLorenzo, {A. M.} and J. Dancis and Balis, {M. E.} and Y{\"u}, {T. F.} and Cox, {R. P.}",
year = "1976",
language = "English (US)",
volume = "57",
pages = "1600--1605",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Hypoxanthine phosphoribosyltransferase activity in intact fibroblasts from patients with X linked hyperuricemia

AU - Holland, M. J C

AU - DiLorenzo, A. M.

AU - Dancis, J.

AU - Balis, M. E.

AU - Yü, T. F.

AU - Cox, R. P.

PY - 1976

Y1 - 1976

N2 - Discordance between clinical phenotype and the level of a mutant enzyme activity may reflect differences between enzyme function in vivo and that measured by the customary enzyme assays on cell extracts. In the present study, the conversion of hypoxanthine to phosphorylated products was measured in intact skin fibroblasts and in cell extracts from seven patients with mutant hypoxanthine guanine phosphoribosyltransferase (HPRT) and six control subjects. The patient's phenotypes ranged from asymptomatic hyperuricemia to the Lesch Nyhan syndrome. Although there was a general correlation between the HPRT activity in cell extracts assayed by the usual methods and the function of the purine salvage pathway in patients, as reflected by urinary oxypurine excretion, there were notable exceptions. A more accurate appraisal of the functioning of the pathway at the cellular level is achieved by measuring the conversion of substrate to product in the intact cell at physiological concentrations of substrates, activators, and product and metabolite inhibitors, and in a physiological ionic environment. In one of the seven patients, the standard enzyme assay indicated normal function, whereas measurements in the intact cell exposed severe dysfunction of the salvage system. In another, the standard assay suggested a severe deficiency not evident in the intact cell or in the patient.

AB - Discordance between clinical phenotype and the level of a mutant enzyme activity may reflect differences between enzyme function in vivo and that measured by the customary enzyme assays on cell extracts. In the present study, the conversion of hypoxanthine to phosphorylated products was measured in intact skin fibroblasts and in cell extracts from seven patients with mutant hypoxanthine guanine phosphoribosyltransferase (HPRT) and six control subjects. The patient's phenotypes ranged from asymptomatic hyperuricemia to the Lesch Nyhan syndrome. Although there was a general correlation between the HPRT activity in cell extracts assayed by the usual methods and the function of the purine salvage pathway in patients, as reflected by urinary oxypurine excretion, there were notable exceptions. A more accurate appraisal of the functioning of the pathway at the cellular level is achieved by measuring the conversion of substrate to product in the intact cell at physiological concentrations of substrates, activators, and product and metabolite inhibitors, and in a physiological ionic environment. In one of the seven patients, the standard enzyme assay indicated normal function, whereas measurements in the intact cell exposed severe dysfunction of the salvage system. In another, the standard assay suggested a severe deficiency not evident in the intact cell or in the patient.

UR - http://www.scopus.com/inward/record.url?scp=0017196335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017196335&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 1600

EP - 1605

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -